Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo

[1]  C. Croce,et al.  Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development. , 2022, Cancer cell.

[2]  P. Tassone,et al.  A p53‐Dependent Tumor Suppressor Network Is Induced by Selective miR‐125a‐5p Inhibition in Multiple Myeloma Cells , 2014, Journal of cellular physiology.

[3]  P. Tassone,et al.  Mir-34: A New Weapon Against Cancer? , 2014, Molecular therapy. Nucleic acids.

[4]  Jocelyn T. Kim,et al.  Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias. , 2014, Blood.

[5]  P. Tassone,et al.  MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. , 2014, Current pharmaceutical biotechnology.

[6]  T. Chevassut,et al.  The Genetic Architecture of Multiple Myeloma , 2014, Advances in hematology.

[7]  W. Kuo,et al.  miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. , 2014, Cancer research.

[8]  P. Tassone,et al.  Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity , 2014, Oncotarget.

[9]  M. Cannataro,et al.  In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma , 2014, PloS one.

[10]  P. Tassone,et al.  In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells , 2014, PloS one.

[11]  P. Tassone,et al.  Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma , 2014, BioMed research international.

[12]  M. Komada,et al.  ERK-Dependent Downregulation of Skp2 Reduces Myc Activity with HGF, Leading to Inhibition of Cell Proliferation through a Decrease in Id1 Expression , 2013, Molecular Cancer Research.

[13]  P. Tassone,et al.  miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells , 2013, Cell cycle.

[14]  P. Tassone,et al.  miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease , 2013, Journal of cellular physiology.

[15]  B. Li,et al.  MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R , 2013, Oncogene.

[16]  D. MacEwan,et al.  Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression , 2013, Cell cycle.

[17]  P. Tassone,et al.  Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma , 2013, Expert opinion on biological therapy.

[18]  Mario Boccadoro,et al.  Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia , 2013, Clinical Cancer Research.

[19]  L. Staudt,et al.  Control of autophagic cell death by caspase-10 in multiple myeloma. , 2013, Cancer cell.

[20]  T. Paíno,et al.  Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication , 2013, Haematologica.

[21]  N. Munshi,et al.  Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth , 2013, Clinical Cancer Research.

[22]  M. Cannataro,et al.  In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma , 2013, Oncotarget.

[23]  Yumeng Sun,et al.  Diverse functions of miR-125 family in different cell contexts , 2013, Journal of Hematology & Oncology.

[24]  N. Munshi,et al.  miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 , 2012, Cell Death and Disease.

[25]  M. Negrini,et al.  Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence , 2012, Clinical Cancer Research.

[26]  P. L. Bergsagel,et al.  Molecular pathogenesis of multiple myeloma and its premalignant precursor. , 2012, The Journal of clinical investigation.

[27]  M. Negrini,et al.  DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma , 2012, Oncotarget.

[28]  A. Waage,et al.  Addiction to c-MYC in multiple myeloma. , 2012, Blood.

[29]  A. Borkhardt,et al.  MiR-125 in normal and malignant hematopoiesis , 2012, Leukemia.

[30]  P. Tassone,et al.  Molecular targets for the treatment of multiple myeloma. , 2012, Current cancer drug targets.

[31]  P. Tassone,et al.  Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma , 2012, Current cancer drug targets.

[32]  A. Bader.  miR-34 – a microRNA replacement therapy is headed to the clinic , 2012, Front. Gene..

[33]  Ryan M. O’Connell,et al.  MicroRNA-125b Potentiates Macrophage Activation , 2011, The Journal of Immunology.

[34]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[35]  I. Jurisica,et al.  NAViGaTing the Micronome – Using Multiple MicroRNA Prediction Databases to Identify Signalling Pathway-Associated MicroRNAs , 2011, PloS one.

[36]  R. Carrasco,et al.  Pathogenesis of myeloma. , 2011, Annual review of pathology.

[37]  N. Munshi,et al.  A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells , 2011, Leukemia.

[38]  J. Gera,et al.  IL-6-induced Enhancement of c-Myc Translation in Multiple Myeloma Cells , 2010, The Journal of Biological Chemistry.

[39]  Huey-Jen Lin,et al.  Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. , 2010, Cancer cell.

[40]  C. Croce,et al.  Targeting microRNAs in cancer: rationale, strategies and challenges , 2010, Nature Reviews Drug Discovery.

[41]  Yong Li,et al.  Negative Regulation of the Tumor Suppressor p53 Gene by MicroRNAs , 2010, Oncogene.

[42]  Sabyasachi Das,et al.  MicroRNA 125b inhibition of B cell differentiation in germinal centers. , 2010, International immunology.

[43]  L. Staudt,et al.  IRF4: Immunity. Malignancy! Therapy? , 2009, Clinical Cancer Research.

[44]  F. Slack,et al.  MicroRNAs as potential cancer therapeutics , 2008, Oncogene.

[45]  E. Knudsen,et al.  Stress and IGF-I Differentially Control Cell Fate through Mammalian Target of Rapamycin (mTOR) and Retinoblastoma Protein (pRB)* , 2008, Journal of Biological Chemistry.

[46]  C. Croce,et al.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.

[47]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[48]  Kuo-I Lin,et al.  Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown. , 2007, Cancer research.

[49]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[50]  A I Pick,et al.  THE TREATMENT OF MULTIPLE MYELOMA , 1948, Harefuah.

[51]  D. Chauhan,et al.  Bone marrow microenvironment and the identification of new targets for myeloma therapy , 2009, Leukemia.

[52]  Tsung-Cheng Chang,et al.  Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.